Français
Deutsch
Español
Italiano
Português
日本語
한국어
Русский
Compare the Best Prostate Supplements for Men on the Market (Update)
May 01, 2023Experimental weight loss drugs aim to surpass stars like Ozempic and Wegovy
Jul 01, 2023Billings residents turn to alternative health services to maintain wellness
Jul 27, 2023Bloating Pain? Reviewers Say this Supplement Is the ‘Only Thing That Seems to Work’
Jul 30, 2023What is fish oil good for? Benefits and if you can take it every day
Aug 14, 2023Novo Nordisk is aware of 10 deaths from compounded weight-loss drug copies | Reuters
Nov 06, 2024Sign up here.
Reporting by Maggie Fick; Editing by Jan Harvey, Emelia Sithole-Matarise and Louise Heavens
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Thomson Reuters
Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global perspective. In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year award in the Beat Coverage of the Year category. Since November 2023, she has also been participating in Reuters coverage related to the Israel-Hamas war. Previously based in Nairobi and Cairo for Reuters and in Lagos for the Financial Times, Maggie got her start in journalism in 2010 as a freelancer for The Associated Press in South Sudan.
Thomson Reuters
Based in Copenhagen, Jacob oversees reporting from Denmark, Iceland, Greenland and the Faroe Islands. He specializes in security and geopolitics in the Arctic and Baltic Sea regions, as well as large corporates such as obesity drug maker Novo Nordisk, brewer Carlsberg and shipping group Maersk. Before moving to Copenhagen in 2016, Jacob spent seven years in Moscow covering Russia's oil and gas industry for Dow Jones Newswires and The Wall Street Journal, followed by four years in Singapore covering energy markets for WSJ and Reuters.